Supplement Documents for Financial Results Q1 FY12/21
May 14, 2021
To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs
Chiome Bioscience Inc.
Agenda
１．Overview of Q1 FY12/21 "Financial results"
２．Overview of Q1 FY12/21 "Operation highlights"
Appendix.
Corporate information
Pipeline information
2 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. |
Overview of
Q1 FY12/21 "Financial results"
Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.
3 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. |
Financial results: Profit and Loss
(JPY in millions)
Q1 FY2020 | Q1 FY2021 | Increase | ||||
(decrease) | ||||||
Net sales | 90 | 246 | 155 | |||
Drug Discovery & | ０ | 103 | 103 | |||
Development | ||||||
Drug Discovery | 89 | 143 | 53 | • Growth in business with domestic | ||
Support | pharmaceutical companies | |||||
COS/SGA | 517 | 401 | (115) | |||
R&D Expense | 342 | 216 | (126) | • Decrease in the cost of study drug | ||
manufacturing and CRO in CBA-1205 | ||||||
program | ||||||
Other costs | 174 | 185 | 10 | • Up in material costs due to increased | ||
business transactions | ||||||
Operating Loss | (426) | (155) | 271 | |||
Ordinary Loss | (424) | (149) | 275 | |||
Net Loss | (425) | (160) | 264 | |||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | 4 |
Financial results: Balance Sheet
(JPY in millions) | ||
As of Dec. 31, 2020 | As of Mar. 31, 2021 | |
Current assets | 3,248 | 3,293 |
（Cash on hand in banks) | 2,686 | 2,580 |
(Other current assets) | 562 | 713 |
Non-current assets | 246 | 243 |
Total assets | 3,494 | 3,537 |
Current Liabilities | 342 | 377 |
Non-current liabilities | 41 | 41 |
Total liabilities | 384 | 419 |
Total net assets | 3,109 | 3,117 |
Total liabilities and net assets | 3,494 | 3,537 |
5 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
This is an excerpt of the original content. To continue reading it, access the original document here.